Botulinum toxin A versus bupivacaine trigger point injections for the treatment of myofascial pain syndrome: A randomised double blind crossover study

Atlsas, 1996, The Maine Lumbar Spine Study, part III: 1-year outcomes of surgical and nonsurgical management of lumbar spinal stenosis., Spine, 21, 1787, 10.1097/00007632-199608010-00012

Chatman, 1997, The patient specific functional scale: measurement properties in patients with knee dysfunction., Phys Ther, 77, 820, 10.1093/ptj/77.8.820

Cheshire, 1994, Botulinum toxin in the treatment of myofascial pain syndrome., Pain, 59, 65, 10.1016/0304-3959(94)90048-5

Childers, 1998, Treatment of painful muscle syndromes with botulinum toxin. A review., J Back Musculoskeletal Rehabil, 10, 89, 10.3233/BMR-1998-10205

Daltroy, 1996, The North American Spine Society lumbar spine outcome assessment instrument: reliability and validity tests., Spine, 21, 741, 10.1097/00007632-199603150-00017

Deyo, 1998, Outcome measures for low back pain research: a proposal for standardized use., Spine, 23, 2003, 10.1097/00007632-199809150-00018

Foster, 2001, Botulinum toxin A and chronic low back pain. A randomized double-blind study., Neurology, 56, 1290, 10.1212/WNL.56.10.1290

Freund, 2000, Treatment of whiplash associated with neck pain with botulinum toxin A: a pilot study., J Rheumatol, 27, 481

Hallet, 2000, How does botulinum toxin work?, Ann Neurol, 48, 7, 10.1002/1531-8249(200007)48:1<7::AID-ANA2>3.0.CO;2-O

Hubbard, 1993, Myofascial trigger points show spontaneous needle EMG activity., Spine, 18, 1803, 10.1097/00007632-199310000-00015

Lang, 2000, A pilot study of botulinum toxin type A (BTX A) administered using a novel injection technique for the treatment of myofascial pain., Am J Pain Manage, 10, 108

OSullivan, 1999, Rescue of exocytosis in botulinum toxin A-poisoned chromaffin cells by expression of cleavage-resistant SNAP-25., J Biol Chem, 274, 36897, 10.1074/jbc.274.52.36897

Porta, 2000, A comparative trial of botulinum toxin type A and methylprednisolone for the treatment of myofascial pain syndrome and pain from chronic muscle spasm., Pain, 85, 101, 10.1016/S0304-3959(99)00264-X

Royal, 2003, Botulinum toxins in pain management., Phys Med Rehabil Clin N Am, 14, 805, 10.1016/S1047-9651(03)00063-9

Satkunam, 2003, Rehabilitation medicine 3. Management of adult spasticity., Can Med Assoc J, 169, 1173

Stratford, 1995, Assessing disability and change on individual patients: a report of a patient specific measure., Physiother Can, 47, 258, 10.3138/ptc.47.4.258

Travel, 1952, The myofascial genesis of pain., Postgrad Med, 11, 425, 10.1080/00325481.1952.11694280

Westaway, 1998, The patient specific functional scale: validation of its use in persons with neck dysfunction., J Orthop Sports Phys Ther, 27, 331, 10.2519/jospt.1998.27.5.331

Wheeler, 1998, A randomized double-blind prospective pilot study of botulinum toxin injection for refractory, unilateral, cervicothoracic paraspinals myofascial pain syndrome., Spine, 23, 1662, 10.1097/00007632-199808010-00009

Wheeler, 2001, Botulinum toxin A for the treatment of chronic neck pain., Pain, 94, 255, 10.1016/S0304-3959(01)00358-X

Zink, 2003, The acute myotoxic effects of bupivacaine and ropivacaine after continuous peripheral nerve blockades., Anesth Analg, 97, 1173, 10.1213/01.ANE.0000080610.14265.C8